April 29th 2017 Baxter International Inc (NYSE.BAX) through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision
On May 1st - the day we published the recommendation - the stock could be bought at 55.43$ per share.
On May 5th - the stock could be sold at 56$ per share
Investors profit 1%
The recommendation is no longer valid.
Sophiris Bio (NASDAQ.SPHS) is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases.
We began our coverage of the company on December 14th 2016. The stock was trading at $2.9 at the moment of our recommendation start.
The company lead drug in development is PRX302 (topsalysin). With the drug Sophiris Bio has successfully passed Phase 2а of the study in prostate cancer. Despite that the study primary endpoint was only safety of the drug - it showed the drug ability to destroy tumor cells for at least 6 months (monitoring period in the study) in 11 of 18 total participants. The drug showed good tolerability during the study
Now the company needs to do a Phase 2b trial to determine optimal dosage of the drug. The Phase 2a was completed in June 2016. In August 2016 the company did a secondary offering and raised $30M which is enough to fund the Phase2b study. The study has been initiated in Q1 2017. The resusts are dure to be published in Q1 2018.
Also Sophiris Bio has successfully completed Phase 3 study in benign prostatic hyperplasia. The company announced that a second Phase 3 study is required before submission to the FDA for Topsalysin marketing approval in the indication. The second Phase 3 estimated cost announced by Sophiris is $53M. The company announced that it will initiate the study only after a partnership or other options are concluded with a large biopharma to fund the Phase 3.